

Condensed interim consolidated financial statements
[Unaudited]

Emblem Corp.

[formerly Saber Capital Corp.]

For the three and nine months ended September 30, 2017 and 2016

Emblem Corp.

[formerly Saber Capital Corp.]

NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the condensed interim consolidated financial statements, they must be accompanied by a notice indicating that the interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements of Emblem Corp. [the “Company”] have been prepared by and are the responsibility of the Company’s management.

The Company’s independent auditor has not performed a review of these condensed interim consolidated financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity’s auditor.

Emblem Corp.

[formerly Saber Capital Corp.]

Condensed interim consolidated statements of financial position

[Unaudited]

[Expressed in Canadian dollars]

As at	September 30, 2017	December 31, 2016
	\$	\$
Assets		
Current		
Cash and cash equivalents	16,628,842	26,202,542
Trade and other receivables [note 5]	1,528,095	417,440
Prepaid expenses	231,127	256,644
Inventory [note 7]	1,462,914	748,188
Biological assets [note 6]	626,676	124,434
Due from related parties [note 13]	52,093	—
	<u>20,529,747</u>	<u>27,749,248</u>
Equipment deposits	358,825	663,813
Property, plant and equipment [note 8]	26,965,065	9,483,867
	<u>47,853,637</u>	<u>37,896,928</u>
Liabilities and shareholders' equity		
Current		
Trade and other payables	3,710,879	2,295,673
Provisions [note 10]	600,000	600,000
Due to related parties	—	59,690
	<u>4,310,879</u>	<u>2,955,363</u>
Long-term debt [note 11]	<u>5,372,663</u>	<u>5,334,613</u>
	<u>9,683,542</u>	<u>8,289,976</u>
Shareholders' equity		
Common shares [note 12]	60,287,324	47,148,696
Special shares	534,959	534,959
Warrants [note 12]	6,920,050	4,678,264
Stock options [note 12]	1,993,234	548,587
Deficit	(31,565,472)	(23,303,554)
Total shareholders' equity	<u>38,170,095</u>	<u>29,606,952</u>
	<u>47,853,637</u>	<u>37,896,928</u>

Subsequent events [note 15]

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Approved on behalf of the Board:

s/Gordon Fox
Directors/Jeffrey Fineberg
Director

Emblem Corp.
[formerly Saber Capital Corp.]

Condensed interim consolidated statements of operations and comprehensive loss

[Unaudited]
[Expressed in Canadian dollars]

For the three and nine months ended September 30

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2017	2016	2017	2016
	\$	\$	\$	\$
Revenue	592,943	29,250	2,034,692	38,250
Cost of sales <i>[note 7]</i>	1,387,555	367,556	3,881,338	737,136
Unrealized gain from changes in fair value of biological assets <i>[note 6]</i>	(844,491)	(378,612)	(1,807,428)	(763,496)
Gross profit (loss)	49,879	40,306	(39,218)	64,610
Expenses				
General and administrative	934,026	402,040	3,161,323	1,132,687
Research and development	114,334	233,991	312,594	625,984
Selling and marketing	885,434	203,493	2,358,688	512,135
Depreciation	277,305	173,408	770,685	468,318
Stock-based compensation <i>[note 12]</i>	562,410	119,332	1,457,062	285,990
Advances to associate <i>[note 9]</i>	—	169,676	—	406,963
Loss before the following	(2,723,630)	(1,261,634)	(8,099,570)	(3,367,467)
Interest expense, net	48,226	250,838	164,672	674,884
Other (income) expense	39,976	25,000	(2,324)	125,000
Change in fair value of financial instruments <i>[note 10]</i>	—	4,425,303	—	4,425,303
Dividend on Class A preferred shares <i>[note 10]</i>	—	(424,643)	—	—
Net loss and comprehensive loss	(2,811,832)	(5,538,132)	(8,261,918)	(8,592,654)
Basic and diluted loss per ordinary share	(0.03)	(0.14)	(0.10)	(0.31)
Weighted average number of ordinary shares outstanding – basic and diluted	85,216,572	38,867,197	83,756,492	27,572,414

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Emblem Corp.

[formerly Saber Capital Corp.]

Condensed interim consolidated statements of changes in shareholders' equity (deficiency)

[Unaudited]

[Expressed in Canadian dollars]

	Common shares		Special shares		Warrants		Stock options		Deficit	Total
	#	\$	#	\$	#	\$	#	\$	\$	\$
Balance, January 1, 2016	21,638,900	1,580,125	—	—	10,516,240	958,174	3,040,000	99,512	(5,914,908)	(3,277,097)
Private placement issuance	12,565,764	7,359,889	—	—	6,282,882	703,312	—	—	—	8,063,201
Share issuance costs	127,038	(284,494)	—	—	63,519	(26,889)	—	—	—	(311,383)
Conversion of shares	17,032,520	11,748,650	—	—	—	—	—	—	—	11,748,650
Reclassification of warrants	—	—	—	—	1,180,950	337,500	—	—	—	337,500
Stock options issued	—	—	—	—	—	—	1,830,000	285,990	—	285,990
Net loss and comprehensive loss	—	—	—	—	—	—	—	—	(8,592,654)	(8,592,654)
Balance, September 30, 2016	51,364,222	20,404,170	—	—	18,043,591	1,972,097	4,870,000	385,502	(14,507,562)	8,254,207
Balance, January 1, 2017	65,650,817	47,148,696	14,065,285	534,959	29,246,230	4,678,264	4,833,333	548,587	(23,303,554)	29,606,952
Shares and warrants issued to brokers for December 2016 financing	209,037	213,217	—	—	104,518	27,175	—	—	—	240,392
Shares issued to settle an obligation [note 12]	130,435	163,784	—	—	—	—	—	—	—	163,784
Stock options and warrants exercised [note 12]	924,024	788,244	—	—	(904,024)	(251,863)	(20,000)	(12,414)	—	523,967
Stock options forfeited	—	—	—	—	—	—	(183,334)	(20,805)	—	(20,805)
Stock options issued [note 12]	—	—	—	—	—	—	1,445,000	1,013,505	—	1,013,505
Restricted shares issued as share-based compensation [note 12]	300,000	—	—	—	—	—	—	464,361	—	464,361
Private placement issuance [note 12]	4,385,668	13,200,861	—	—	2,192,834	2,719,114	—	—	—	15,919,975
Private placement issuance costs [note 12]	—	(1,227,478)	—	—	—	(252,640)	—	—	—	(1,480,118)
Net loss and comprehensive loss	—	—	—	—	—	—	—	—	(8,261,918)	(8,261,918)
Balance, September 30, 2017	71,599,981	60,287,324	14,065,285	534,959	30,639,558	6,920,050	6,074,999	1,993,234	(31,565,472)	38,170,095

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Emblem Corp.

[formerly Saber Capital Corp.]

Condensed interim consolidated statements of cash flows

[Unaudited]

[Expressed in Canadian dollars]

	Nine Months Ended September 30,	
	2017	2016
	\$	\$
Operating activities		
Net loss and comprehensive loss for the period	(8,261,918)	(8,592,654)
Items not affecting cash		
Unrealized gain from changes in fair value of biological assets <i>[note 6]</i>	(1,807,428)	(763,496)
Non-cash interest	38,050	478,405
Depreciation	770,685	468,318
Other non-cash expense	59,458	100,000
Advances to associate	-	406,963
Stock-based compensation	1,457,062	285,990
Change in fair value of financial instruments	-	4,425,303
	(7,744,091)	(3,191,171)
Change in non-cash operating working capital		
Prepaid expenses	25,517	-
Inventory	(714,726)	(8,076)
Biological assets <i>[note 6]</i>	1,305,186	-
Trade and other receivables	(1,110,655)	48,390
Trade and other payables	(616,448)	74,341
Due to/from related parties	(69,483)	-
Cash used in operating activities	(8,924,700)	(3,076,516)
Financing activities		
Proceeds from long-term debt	-	325,000
Stock options and warrants exercised	523,967	-
Cash flows from private placements, net of cash issuance costs	14,439,857	7,751,818
Cash provided by financing activities	14,963,824	8,076,818
Investing activities		
Purchase of property, plant and equipment, including deposits	(15,612,823)	(1,061,521)
Investment in and advances to associate	-	(531,847)
Cash used in investing activities	(15,612,823)	(1,593,368)
(Decrease) increase in cash and cash equivalents during the period	(9,573,700)	3,406,934
Cash and cash equivalents, beginning of period	26,202,542	1,236,646
Cash and cash equivalents, end of period	16,628,842	4,643,580

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Emblem Corp.

[formerly Saber Capital Corp.]

Notes to condensed interim consolidated financial statements

[Unaudited]

[Expressed in Canadian dollars]

September 30, 2017 and 2016

1. Nature of business

Emblem Corp. ["Emblem" or the "Company"] was incorporated on February 25, 2008 pursuant to the *Business Corporations Act* (British Columbia) under the name "Kristina Capital Corp." and was classified as a Capital Pool Company as defined in Policy 2.4 of the TSX Venture Exchange ["TSXV"]. The Company changed its name to "Saber Capital Corp." on January 19, 2011.

9045538 Canada Inc. (f/k/a KindCann Holdings Limited and Emblem Corp.) ["KindCann"] was incorporated on October 8, 2014 pursuant to the *Canada Business Corporation Act* [the "CBCA"] under the name "KindCann Holdings Limited". KindCann changed its name to "Emblem Corp." on September 1, 2016 and further changed its name to "9045538 Canada Inc." on December 5, 2016.

On December 6, 2016, the Company closed its qualifying transaction [the "Transaction"] with KindCann. The Transaction was completed pursuant to a plan of arrangement [the "Plan of Arrangement"] under the CBCA pursuant to which the shareholders of KindCann completed a reverse take-over of the Company. In connection with the Transaction the Company:

- (a) changed its name from "Saber Capital Corp." to "Emblem Corp.";
- (b) consolidated its common shares at a ratio of one (1) post-consolidation common share [each a "Common Share"] for every four (4) pre-consolidation common shares]; and
- (c) continued from a corporation governed by the laws of British Columbia to a corporation governed under the CBCA.

Pursuant to the Plan of Arrangement, the shareholders of KindCann received one (1) Common Share for each common share of KindCann registered in the names of such shareholders. Holders of KindCann's special non-voting shares also received one (1) special non-voting share of the Company [each a "Special Non-Voting Share"] for each special non-voting share of KindCann registered in the names of such shareholders. Holders of KindCann's options and warrants outstanding at the time of the closing of the Transaction also received equivalent securities of the Company exercisable for or convertible into Common Shares.

Prior to completion of the Transaction, the Company completed a brokered private placement by issuing 18,781,985 subscription receipts at a price of \$1.15 for gross proceeds of \$21,599,283. On closing of the Transaction, each subscription receipt was exchanged, without payment of any additional consideration, for one unit ["Unit"] of the Company, comprising one (1) Common Share and one-half of one (1/2) warrant [each whole warrant, a "Warrant"]. Each Warrant is exercisable to purchase one (1) Common Share at an exercise price of \$1.75 per Common Share for a period of 36 months. Concurrent with completion of the Transaction, the Company completed a brokered financing pursuant to a TSXV short form offering document by issuing 1,739,130 Units for gross proceeds of \$2,000,000.

Following these changes, KindCann amalgamated with Saber Acquisition Co., a wholly-owned subsidiary of the Company formed solely for the purpose of facilitating the Transaction, to form 9526820 Canada Inc. ["9526820"]. Immediately thereafter, 9526820 amalgamated with its wholly owned subsidiaries, Emblem Cannabis Corporation (formerly KindCann Limited), KindCann Realty Limited and 9845992 Canada Limited (formerly Oakbank Holdings Limited). The amalgamated entity was renamed "Emblem Cannabis Corporation" ["ECC"].

Emblem Corp.

[formerly Saber Capital Corp.]

Notes to condensed interim consolidated financial statements

[Unaudited]

[Expressed in Canadian dollars]

September 30, 2017 and 2016

Following completion of the Transaction, the Company had 64,936,028 Common Shares issued and outstanding. In addition, an aggregate of 47,936,972 Common Shares were reserved for issuance in connection with the Company's outstanding Special Non-Voting Shares, options, warrants and compensation options.

Effective upon the closing of the Transaction, as a result of the reverse take-over of the Company by the shareholders of KindCann and to align the financial years of the Company to that of KindCann, the financial year of the Company has been changed from January 31 of each year to December 31 of each year.

Upon issuance of the final exchange bulletin of the TSXV providing final acceptance of the Transaction, the Company ceased to be a Capital Pool Company (as such term is defined in the policies of the TSXV) and recommenced trading on the TSXV on December 12, 2016 under the symbol "EMC".

On August 26, 2015, ECC received its initial licence that permitted ECC to produce cannabis [the "Licence"]. The Licence was amended on July 27, 2016 to allow for the sale of cannabis to the public and to permit increased production. The Licence was further amended on April 28, 2017 to authorize ECC to produce cannabis oils, and was amended again on October 6, 2017 to remove restrictions on the amount of marijuana (in all forms) to be produced and sold by Emblem. On November 3, 2017, ECC received a subsequent amendment to permit ECC to complete the sale of bottled cannabis oil. The Licence has a current term ending on July 26, 2019. Emblem's production operations are located in Paris, Ontario.

In addition to its 100% ownership of ECC, the Company also owns a 50% interest in GrowWise Health Limited ["GrowWise"], a corporation incorporated under the *Business Corporation Act* [Ontario]. The Company has an option to acquire all of the remaining shares of GrowWise at any time after December 31, 2017 for fifty percent (50%) of the greater of GrowWise's net book value and \$1.00. The option price is currently expected to be \$1.00. Refer to note 9 for additional details.

Emblem's head office and registered office is located at 36 York Mills Road, Suite 500, Toronto, Ontario M2P 2E9.

2. Basis of preparation

The unaudited condensed interim consolidated financial statements ["financial statements"] were prepared using the same accounting policies and methods as those used in the Company's consolidated financial statements for the year ended December 31, 2016. These condensed interim consolidated financial statements have been prepared in compliance with IAS 34 - *Interim Financial Reporting*. Accordingly, certain disclosures normally included in annual financial statements prepared in accordance with International Financial Reporting Standards ["IFRS"] have been omitted or condensed. These condensed interim consolidated financial statements should be read in conjunction with the Company's consolidated financial statements for the year ended December 31, 2016.

These condensed interim consolidated financial statements were approved and authorized for issuance by the board of directors of the Company [the "Board of Directors"] on November 27, 2017.

Emblem Corp.

[formerly Saber Capital Corp.]

Notes to condensed interim consolidated financial statements

[Unaudited]

[Expressed in Canadian dollars]

September 30, 2017 and 2016

3. New standards, amendments and interpretations adopted by the Company

The following new accounting standards applied or adopted during the nine-month period ended September 30, 2017 had no material impact on the financial statements:

[i] IAS 7 – Statement of Cash Flows [“IAS 7”]

On January 1, 2017, the Company adopted the amended version of IAS 7 - *Statement of Cash Flows*. The amendments require disclosures to evaluate changes in liabilities arising from financing activities, including both cash flow and non-cash changes. These amendments do not have a material impact on the condensed interim consolidated financial statements. The Company is not required to include the additional disclosures in its condensed consolidated interim financial statements and will disclose this information prospectively in its annual consolidated financial statements for the year ended December 31, 2017.

4. New standards and interpretations not yet adopted

The Company has not applied the following new and revised IFRS that have been issued but are not yet effective:

[i] IFRS 9 - Financial Instruments [“IFRS 9”]

In July 2014, the IASB issued the final version of IFRS 9, which reflects all phases of the financial instruments project and replaces IAS 39 - *Financial Instruments: Recognition and Measurement* and all previous versions of IFRS 9. The standard introduces new requirements for classification and measurement, impairment, and hedge accounting. IFRS 9 is effective for annual periods beginning on or after January 1, 2018, with early application permitted. Retrospective application is required, but restatement of comparative information is not compulsory. The Company is in the process of evaluating the impact of IFRS 9 on the Company's consolidated financial statements.

[ii] IFRS 15 - Revenue from Contracts with Customers [“IFRS 15”]

In May 2014, the IASB issued IFRS 15, which covers principles for reporting about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The core principle of the new standard is that an entity recognizes revenue to represent the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also provides a model for the recognition and measurement of gains or losses of non-financial assets. IFRS 15 is effective for annual periods beginning on or after January 1, 2018. The standard permits the use of either full or modified retrospective application. This new accounting guidance will also result in enhanced disclosures about revenue. The Company is evaluating the effect that IFRS 15 will have on its consolidated financial statements and related disclosures, as well as the transition method to apply the new standard.

Emblem Corp.

[formerly Saber Capital Corp.]

Notes to condensed interim consolidated financial statements

[Unaudited]

[Expressed in Canadian dollars]

September 30, 2017 and 2016

[iii] IFRS 16 - Leases ["IFRS 16"]

In January 2016, the IASB issued IFRS 16, which specifies how an IFRS reporter will recognize, measure, present and disclose leases. The standard provides a single lessee accounting model, requiring lessees to recognize assets and liabilities for all leases unless the lease term is 12 months or less or the underlying asset has a low value. Lessors continue to classify leases as operating or finance, with IFRS 16's approach to lessor accounting substantially unchanged from its predecessor, IAS 17. IFRS 16 is effective for annual reporting periods beginning on or after January 1, 2019, and a lessee shall either apply IFRS 16 with full retrospective effect or alternatively not restate comparative information but recognize the cumulative effect of initially applying IFRS 16 as an adjustment to opening equity at the date of initial application. Early adoption is permitted if IFRS 15 has also been adopted. The Company is in the process of evaluating the impact of IFRS 16 on the Company's consolidated financial statements.

[iv] IFRS 2 – Share-based payments ["IFRS 2"]

IFRS 2 has been amended to address [i] certain issues related to the accounting for cash-settled awards, and [ii] the accounting for equity settled awards that include a "net settlement" feature in respect of employee withholding taxes. IFRS 2 is effective for annual periods beginning on or after January 1, 2018. The Company is in the process of evaluating the amendments to IFRS 2 on the Company's consolidated financial statements.

[v] IFRIC 23 – Uncertainty over Income Tax Treatment ["IFRIC 23"]

In June 2017, the IASB issued IFRIC 23, which clarifies the accounting for uncertainties in income taxes. IFRIC 23 is effective for annual period beginning on or after January 1, 2019. The requirements are applied by recognizing the cumulative effect of initially applying them in retained earnings, or in other appropriate components of equity, at the start of the reporting period in which the Company first applies them, without adjusting comparative information. Full retrospective application is permitted, if the Company can do so without using hindsight. The Company is in the process of evaluating the impact of IFRIC 23 on the Company's consolidated financial statements.

5. Trade and other receivables

	September 30, 2017	December 31, 2016
	\$	\$
Trade receivables	224,493	221,116
Sales tax receivable	1,287,036	190,160
Other receivables	16,566	6,164
	1,528,095	417,440

In October and November 2017, \$922,653 of sales tax refunds were received from the Canada Revenue Agency.

Emblem Corp.

[formerly Saber Capital Corp.]

Notes to condensed interim consolidated financial statements

[Unaudited]

[Expressed in Canadian dollars]

September 30, 2017 and 2016

6. Biological assets

The changes in the carrying value of biological assets, which consist of cannabis on plants, are as follows:

	\$
Balance as at December 31, 2015	<u>9,125</u>
Net increase in fair value less cost to sell due to biological transformation	805,900
Transferred to inventory upon harvest	(690,591)
Balance as at December 31, 2016	<u>124,434</u>
Net increase in fair value less cost to sell due to biological transformation	1,807,428
Transferred to inventory upon harvest	(1,305,186)
Balance as at September 30, 2017	<u>626,676</u>

All biological assets are current assets. The fair value measurements for biological assets have been categorized as Level 3 fair value based on the inputs used. The significant assumptions used in determining the fair value of cannabis on plants includes:

- [i] Expected yields for cannabis on plants to be harvested, including wastage and the risk over the period;
- [ii] The costs to be incurred at different stages in the growing, drying and selling cycle of the plants were estimated by calculating an average of total growing, drying and selling costs (including customer service) over the projected production period; and
- [iii] The number of weeks plants have been growing as a percentage of total growing weeks was applied to the total fair value per gram, which is determined based on current market prices of medical cannabis.

These estimates are subject to volatility in market prices and a number of uncontrollable factors, which could significantly affect the fair value of biological assets in future periods.

The Company estimates the harvest yields for medical cannabis at various stages of growth. As at September 30, 2017, it is expected that the Company's biological assets will yield approximately 316,700 grams [December 31, 2016 – 104,000 grams] of medical cannabis when harvested. The Company's estimates are, by their nature, subject to change and differences from the anticipated yield will be reflected in the gain or loss on biological assets in future periods.

Emblem Corp.

[formerly Saber Capital Corp.]

Notes to condensed interim consolidated financial statements

[Unaudited]

[Expressed in Canadian dollars]

September 30, 2017 and 2016

7. Inventory

	September 30, 2017 \$	December 31, 2016 \$
Finished goods – dry cannabis	814,288	77,661
Work-in progress – dry cannabis	509,065	577,303
Seeds	26,727	27,398
Packaging and supplies	112,834	65,826
	1,462,914	748,188

The cost of inventory recognized as an expense during the three and nine months ended September 30, 2017 was \$1,387,555 and \$3,881,338 respectively [2016: \$367,556 and \$737,136].

The Company did not have any inventory write-downs during the three or nine months ended September 30, 2017 and 2016.

8. Property, plant and equipment

	Land \$	Building \$	Security equipment \$	Production equipment \$	Computer equipment \$	Furniture and fixtures \$	Total \$
Balance, beginning of period	618,698	7,383,650	700,002	1,229,570	377,193	170,958	10,480,071
Additions	7,931,419	9,471,494	92,552	457,501	159,892	139,025	18,251,883
Cost, September 30, 2017	8,550,117	16,855,144	792,554	1,687,071	537,085	309,983	28,731,954
Accumulated depreciation, beginning of period	—	407,361	266,636	206,261	82,202	33,744	996,204
Depreciation	—	227,187	108,222	216,768	172,154	46,354	770,685
Accumulated depreciation, September 30, 2017	—	634,548	374,858	423,029	254,356	80,098	1,766,889
Net carrying cost, September 30, 2017	8,550,117	16,220,596	417,696	1,264,042	282,729	229,885	26,965,065

Included in building is \$9,356,826 [December 31, 2016 - \$180,271] of assets under construction which are not ready for use and not depreciated as at September 30, 2017.

Emblem Corp.

[formerly Saber Capital Corp.]

Notes to condensed interim consolidated financial statements

[Unaudited]

[Expressed in Canadian dollars]

September 30, 2017 and 2016

Additions made to property, plant and equipment during the nine months ended September 30, 2017 relate mainly to the purchase of land and construction costs associated with increasing the capacity of the Company's current facility.

The Company has entered into commitments for the purchase of property, plant and equipment related to the expansion of its existing production facility at Woodslee Ave. As at September 30, 2017, total future purchase obligations related to this project were \$8,676,205.

	Land	Building	Security equipment	Production equipment	Computer equipment	Furniture and fixtures	Total
	\$	\$	\$	\$	\$	\$	\$
Balance, beginning of year	618,698	6,827,254	668,755	497,065	43,202	101,560	8,756,534
Additions	—	556,396	31,247	732,505	358,995	69,398	1,748,541
Additions through acquisition	—	—	—	—	46,166	—	46,166
Disposals	—	—	—	—	(71,170)	—	(71,170)
Cost, December 31, 2016	618,698	7,383,650	700,002	1,229,570	377,193	170,958	10,480,071
Accumulated depreciation, beginning of year	—	88,982	128,831	55,152	14,314	7,899	295,178
Disposals	—	—	—	—	(12,440)	—	(12,440)
Depreciation	—	318,379	137,805	151,109	80,328	25,845	713,466
Accumulated depreciation, December 31, 2016	—	407,361	266,636	206,261	82,202	33,744	996,204
Net carrying cost, December 31, 2016	618,698	6,976,289	433,366	1,023,309	294,991	137,214	9,483,867

9. Investment in GrowWise

The Company holds a 50% interest in an entity, GrowWise, a company incorporated and operating primarily in the Province of Ontario, Canada. The remaining 50% is held by White Cedar Pharmacy Corporation ["White Cedar"]. Key management of the Company owns approximately 51% of the issued and outstanding shares of White Cedar. The business of GrowWise is to offer education services and other related services to prospective medical marijuana patients in Canada.

As part of the Company's amended shareholder agreement ["Amended Shareholder Agreement"] with White Cedar with respect to GrowWise dated October 31, 2016, the Company is committed to make available to GrowWise an unlimited revolving loan facility in order to fund all of GrowWise's working capital requirements. The advances to

Emblem Corp.

[formerly Saber Capital Corp.]

Notes to condensed interim consolidated financial statements

[Unaudited]

[Expressed in Canadian dollars]

September 30, 2017 and 2016

GrowWise under the facility bear interest at a rate of 10%. Payments of interest on, and the principal of, the facility are without recourse to the assets of White Cedar. Until repayment in full of the facility, GrowWise cannot make distributions to White Cedar or the Company. On October 31, 2016, the Company and White Cedar also executed an option agreement [the "Option Agreement"] whereby the Company also has an option to purchase White Cedar's 50% interest in GrowWise at any time on or after December 31, 2017 for 50% of the net book value of GrowWise's net assets, excluding related party liabilities.

The initial funding commitment prior to the October 31, 2016 Amended Shareholder Agreement was \$500,000 and was previously accounted for as an onerous contract and provided for and expensed in 2014. Such amount was fully funded in 2015 and 2016 and an additional \$527,592 above the \$500,000 commitment was funded in 2016 and prior to October 31, 2016. The Company's initial investment of \$1,000,000 related to GrowWise was impaired in 2014. As at October 31, 2016, the carrying amount of the investment in GrowWise was nil [2015 - nil].

Prior to October 31, 2016, the Company determined that White Cedar had control over GrowWise and the Company as the sole additional 50% shareholder had significant influence. The original shareholder agreement established that decision making power related to GrowWise was with White Cedar. White Cedar also had exposure to variable returns through its 50% ownership interest and entitlement to future distributions and the ability to affect those returns through its decision making power.

On October 31, 2016, with the execution of the Amended Shareholder Agreement and the Option Agreement, the Company assessed whether it had acquired control over GrowWise and determined that the definition of control as defined under IFRS 10 – *Consolidated Financial Statements* was now met.

The fair value of the Company's equity interest in GrowWise before the business combination was determined to be nominal based on the significant deficit that GrowWise has accumulated to date and the current uncertainties associated with the future economic benefits that GrowWise may generate.

The Company also determined that the Option Agreement providing it with the right to acquire White Cedar's interest in GrowWise at a formula price and the expectation is that there will be no equity distributions to the owners of GrowWise prior to the Option Agreement becoming exercisable, means in substance that White Cedar no longer has a present equity ownership in GrowWise and instead the substantial majority of the benefits associated with that equity interest now accrue to the Company. Accordingly, White Cedar's interest in GrowWise from October 31, 2016 is accounted for as a liability rather than as non-controlling interest.

The business combination was accounted for using the purchase method and identified a net working capital deficiency of \$17,248, capital assets of \$46,166 and a liability to White Cedar of \$28,918 representing application of the formula price in the Option Agreement based on circumstances as at October 31, 2016. The purchase price consideration was nil and no intangible assets or goodwill were identified as part of the purchase price equation.

The results of the operations of GrowWise, as well as its assets and liabilities, are now included in the consolidated financial statements of the Company effective October 31, 2016 at 100%.

Emblem Corp.

[formerly Saber Capital Corp.]

Notes to condensed interim consolidated financial statements

[Unaudited]

[Expressed in Canadian dollars]

September 30, 2017 and 2016

As at October 31, 2016, the balance owed by GrowWise to the Company under the facility of \$1,027,592 was determined to be impaired in full, which resulted in an impairment charge of \$39,713 for the three month period ended March 31, 2016 and \$527,592 from the period January 1, 2016 to October 31, 2016. Funding of \$375,116 in 2015 and \$124,884 in 2016 up to October 31, 2016 was applied to the provision recorded in 2014.

The liability to White Cedar was re-measured to \$1 at June 30, 2017 [December 31, 2016 - \$42,301]. This reflects an amended option agreement ["Amended Option Agreement"] between the Company and White Cedar, executed in the second quarter of 2017, that sets the purchase price under the Amended Option Agreement to \$1 if the net book value of GrowWise is less than zero when the option is exercised. The change in the liability of \$42,300 is included in other (income) expense in the condensed interim consolidated statements of operations and comprehensive loss.

10. Class A preferred shares financial liability

KindCann completed private placements in 2014 and 2015 for 701,886 and 349,760 units [the "Pref Share Units"] respectively. Each Pref Share Unit included 20 Class A preferred shares, warrants to acquire 10 common shares and a royalty interest related to the Company's interest in GrowWise. The components of the Pref Share Units were initially recognized based on their fair values. Due to the nominal fair value ascribed to the royalty interests from GrowWise, the proceeds from the private placement were attributed to the Class A preferred shares financial liability and the common share purchase warrants. The Class A preferred shares were non-voting and ranked in priority to the common shares and to any other class of shares with respect to the payment of dividends.

At issuance, it was determined that the Class A preferred shares did not meet the IFRS definition of equity due to the variability of the conversion rate ratio from 1 Class A preferred share to 1 common share or 1 Class A preferred share to 1.25 common shares if KindCann failed to go public by a specified date, mandatory dividends for two years, and certain redemption provisions in the event that KindCann did not pay dividends when due, a cultivation license was not obtained by a specified date, KindCann's producer's license application was rejected by Health Canada or withdrawn, and certain other events of default. Accordingly, the fair value of the Class A preferred shares was treated as a financial liability measured at fair value through profit or loss.

The holders of Class A preferred shares were entitled to cumulative dividends in the amount of \$0.05 per share per annum, payable semi-annually. In 2015, KindCann passed a motion, which was approved by a majority of preferred shareholders, to allow the Board of Directors, at its discretion, to allow these dividends on the Class A preferred shares to be paid in cash or by issuing common shares, with the number of common shares to be determined based on the market price of such shares.

In 2015, a holder of 2,000,000 Class A preferred shares dissented to certain resolutions of KindCann and is seeking to have the Company to repurchase the shares for \$1,000,000. The provision related to a dissenting shareholder of \$600,000 is subject to an ongoing process which will ultimately determine the settlement amount; the outcome may be materially different than the provision recorded.

On August 18, 2016, all outstanding Class A preferred shares were converted into common shares of KindCann. In connection with this conversion, the holders of the Class A preferred shares also surrendered their rights for any dividend that was accrued and unpaid as at the date of conversion. For the three months ended September 30,

Emblem Corp.

[formerly Saber Capital Corp.]

Notes to condensed interim consolidated financial statements

[Unaudited]

[Expressed in Canadian dollars]

September 30, 2017 and 2016

2016, KindCann recognized a recovery of \$424,643 related to the dividends on Class A preferred shares accrued for the six months ended June 30, 2016.

In connection with the conversion of Class A preferred shares into common shares, the Company recognized a fair value adjustment of \$4,087,803 due to an increase in fair value of the Class A preferred shares in excess of the carrying amount of the financial liability.

On August 18, 2016, the Company also recognized a fair value adjustment of \$337,500 related to the reclassification of broker warrants from derivative liabilities to equity.

11. Long-term debt

	September 30, 2017	December 31, 2016
	\$	\$
During the year ended December 31, 2016, the Company entered into a promissory note in the amount of \$5,500,000. The note is secured by first charge on the property and a general security agreement with a fixed charge over all assets of the Company and a share pledge of all ECC and GrowWise shares. Interest-only payments at a rate of 8% per annum are due monthly. The promissory note is repayable in full on December 12, 2019. The Company has an option to repay in full on December 12, 2018.	5,500,000	5,500,000
	5,500,000	5,500,000
Long-term debt is presented net of transaction costs. Transaction costs are recognized in results of operations over the term of the long-term debt using the effective interest rate method.	(127,337)	(165,387)
	5,372,663	5,334,613

12. Share capital**[a] Authorized**

An unlimited number of (a) Common Shares; (b) preferred shares; and (c) Special Non-Voting Shares, are available for issue.

[b] Issued and outstanding

On January 4, 2017, the Company issued 300,000 restricted Common Shares to a non-employee in exchange for services to the Company over a 3 year period. The Common Shares are held in escrow and are released ratably

Emblem Corp.

[formerly Saber Capital Corp.]

Notes to condensed interim consolidated financial statements

[Unaudited]

[Expressed in Canadian dollars]

September 30, 2017 and 2016

over a three-year period as services are received with share-based compensation expense recognized over the same period.

Pursuant to December 2016 financings, the Company accrued for transaction costs in the amount of \$240,392 which were settled in January 2017 by issuance of 209,037 Common Shares and 104,518 Warrants.

In January 2017, the Company issued 100,000 Common Shares to a non-employee to settle an obligation. On January 31, 2017, the Company closed an underwritten private placement [the "Offering"] of 4,385,668 special warrants of the Company [the "Special Warrants"] at a price of \$3.63 per Special Warrant for gross proceeds of \$15,919,975.

Issuance costs for the Offering were \$1,479,167 paid in cash and were allocated to common shares and Warrants in the amount of \$1,226,527 and \$252,640 respectively.

On March 17, 2017, the Company obtained a receipt for a short form prospectus that qualified for distribution the units [the "March Units"] underlying the Special Warrants and, as a result of which, each Special Warrant was automatically exercised for one (1) March Unit. Each March Unit was comprised of one (1) Common Share and one-half of one (1/2) common share purchase warrant [each whole warrant, a "March Warrant"]. Each March Warrant entitles the holder to purchase one (1) Common Share at an exercise price of \$4.75 for a period of 36 months from January 31, 2017. The expiry date of the March Warrants may be accelerated upon notice from the Company if the volume weighted average trading price of the Common Shares is equal to or greater than \$7.00 over a period of 10 consecutive trading days. The fair value of these March Warrants was estimated at \$1.24 per share using the Black-Scholes option pricing model with a market price per Common Share of \$3.02, a risk-free interest rate of 0.92%, an expected annualized volatility of 80% and expected dividend yield of 0%. Gross proceeds of \$15,919,975 were allocated to Common Shares and March Warrants in the amount of \$13,200,861 and \$2,719,114 respectively.

On July 31, 2017, the Company issued a total of 30,435 Common Shares in connection with the granting of an exclusive licence to Emblem pursuant to a white label agreement. Issuance costs for the shares were \$951.

During the nine months ended September 30, 2017: (a) 904,024 share purchase warrants were exercised at an average price of \$0.57; and (b) 20,000 stock options were exercised at a price of \$0.40, for gross proceeds of \$523,967.

[c] Stock options

On March 13, 2017, the Company granted 1,165,000 incentive stock options [the "March Options"] to independent directors, non-executive employees and consultants of the Company. The March Options are exercisable at a price of \$2.58 per share for a period of five years and are subject to vesting as to one-third of the number of March Options granted on each of March 31, 2018, 2019 and 2020.

On April 17, 2017, the Company granted 280,000 incentive stock options [the "April Options"] to a consultant performing investor relations activities and employees of the Company. The April Options are exercisable at a price

Emblem Corp.

[formerly Saber Capital Corp.]

Notes to condensed interim consolidated financial statements

[Unaudited]

[Expressed in Canadian dollars]

September 30, 2017 and 2016

of \$2.60 per share for a period of five years and are subject to vesting as to one-third of the number of April Options granted on each of April 30, 2018, 2019 and 2020.

During the nine months ended September 30, 2017, 20,000 stock options were exercised and 183,334 stock options were forfeited.

Total share-based compensation expense for the three and nine months ended September 30, 2017 was \$562,410 and \$1,457,062 respectively [2016: \$119,332 and \$285,990].

13. Related party transactions**Transactions and balances with related parties**

Prior to the acquisition of GrowWise, all transactions with GrowWise were related party transactions. Details of these transactions are discussed in note 9.

Due from related parties includes \$43,184 receivable from an officer of the company and \$8,909 receivable from White Cedar and its parent company.

14. Loss per ordinary share

Weighted average number of ordinary shares includes Common Shares and Special Non-Voting Shares.

The diluted loss per ordinary share equals basic loss per ordinary share due to the anti-dilutive effect of common share purchase warrants, restricted shares and stock options. The outstanding number and type of securities that could potentially dilute basic net loss per share in the future but that were not included in the computation of diluted net loss per ordinary share because to do so would have reduced the loss per ordinary share (anti-dilutive) for the year presented consist of the following:

	Outstanding	Number of Common Shares issuable on exercise
	#	#
Common share purchase warrants	30,639,558	30,639,558
Restricted shares	300,000	300,000
Stock options	6,074,999	6,074,999
	37,014,557	37,014,557

15. Subsequent events

Emblem Corp.

[formerly Saber Capital Corp.]

Notes to condensed interim consolidated financial statements

[Unaudited]

[Expressed in Canadian dollars]

September 30, 2017 and 2016

On October 3, 2017, the Company announced that it had entered into a Collaboration and Licensing Agreement [the "Agreement"] with Canntab Therapeutics Limited ["Canntab"] of Toronto. Canntab has developed a patent-pending oral sustained release formulation for cannabinoids [the "Sustained Release Product" or the "Product"]. Under the Agreement, Emblem and Canntab will collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of the Sustained Release Product. The Agreement calls for Emblem to make payments to Canntab upon achievement of certain milestones involving stability studies, bio-availability studies and regulatory approval of the Sustained Release Product. The Agreement also calls for Emblem to make royalty payments to Canntab based upon gross sales of the Product.

On October 24, 2017, the Board of Directors approved the construction of a greenhouse facility on the newly acquired lands in Paris, Ontario. The Company intends to break ground on the newly acquired lands in the second quarter of 2018 and to execute on the design and build of its new facility which is expected to be comprised of up to approximately 120,000 square feet of greenhouse space and 50,000 square feet of infrastructure space [the "Paris Road Expansion"]. Once operating at an optimal level, the Company expects the Paris Road Expansion to provide up to an additional 15,000 kilograms of annual production capacity.

On November 16, 2017, the Company closed a "bought deal" offering whereby Eight Capital and a syndicate of underwriters [the "Underwriters"] purchased 7,885,734 units [the "November Units"] and 15,000 convertible unsecured debentures [the "Convertible Debentures"] of the Company at a price per November Unit of \$1.75 [the "Unit Issue Price"] for gross proceeds of \$13,800,034 and a price per Convertible Debenture of \$1,000.00 for gross proceeds of \$15,000,000, for total gross proceeds of \$28,800,034 [the "November Offering"] or total net proceeds of \$26,572,032 after deducting the underwriters' fee of \$1,728,002 and the expenses of the November Offering estimated to be \$500,000.

Each November Unit will be comprised of one (1) Common Share and one common share purchase warrant [each a "November Warrant"]. Each November Warrant shall entitle the holder thereof to purchase one (1) Common Share at an exercise price of \$2.15, for a period of 36 months following the closing of the November Offering.

The Convertible Debentures shall bear interest at a rate of 8.0% per annum from the date of issue, payable semi-annually in arrears on June 30 and December 31 of each year. The Convertible Debentures will have a maturity date of 36 months from the closing date of the Offering [the "Maturity Date"].

The Convertible Debentures will be convertible at the option of the holder into Common Shares at any time prior to the close of business on the Maturity Date at a conversion price of \$1.95 per Common Share [the "Conversion Price"]. Beginning on the date following the Closing date, the Company may force the conversion of all of the principal amount of the then outstanding Convertible Debentures at the Conversion Price on 30 days prior written notice should the daily volume weighted average trading price of the Common Shares be greater than \$2.93, for any 10 consecutive trading days.

As consideration for its services, the Underwriters received a cash commission equal to 6% of the gross proceeds of the November Offering. The Company also issued to the Underwriters non-transferrable compensation warrants in an amount equal to 3% of the gross proceeds of the November Offering divided by the Unit Issue Price. Each compensation warrant will be exercisable into one (1) November Unit at the Unit Issue Price for a period of 36 months following the closing of the November Offering.

Emblem Corp.

[formerly Saber Capital Corp.]

Notes to condensed interim consolidated financial statements

[Unaudited]

[Expressed in Canadian dollars]

September 30, 2017 and 2016

It is currently expected that ninety percent (90%) of the net proceeds from the Offering will be allocated toward the currently unfunded portion of the planning, design, development, construction and implementation (including the purchase of certain designated capital equipment) of the Paris Road Expansion. Although no specific investments are currently contemplated, it is expected that approximately ten percent (10%) of the net proceeds will be invested in, among other things, medical marijuana related technologies, seeds, clinical trials, genetics and research and development initiatives or other infrastructure, all within the industry.

In connection with Nick Dean's appointment as chief executive officer, the Company has approved the grant of an aggregate of 500,000 incentive stock options of the Company [the "Options"] to Mr. Dean. Each Option entitles Mr. Dean to purchase one (1) Common Share at a price of \$1.69 per Common Share for a period of five (5) years from the date of grant. The Options will be subject to the terms of the Company's stock option plan and will vest in three (3) equal tranches with the first tranche to vest on January 15, 2019, the second tranche to vest on January 15, 2020 and the remainder to vest on January 15, 2021.